A Randomised Feasibility Trial With Internet Based Self-help Therapy (IBT)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02499055|
Recruitment Status : Unknown
Verified October 2016 by Mental Health Services in the Capital Region, Denmark.
Recruitment status was: Active, not recruiting
First Posted : July 15, 2015
Last Update Posted : October 12, 2016
Background. In Denmark, about 350,000 persons suffer from anxiety. Public health-care services plan to implement internet based self-help psychotherapy (IBT) to be an important alternative and supplement to ordinary face-to-face therapy. Meta-analyses indicate that the effect of IBT for anxiety disorders seems better than no intervention, and in some instances equal to 'usual therapy'. But studies have been characterised by small sample sizes, high risk for bias, including high dropout.
Objective. The objective of this pilot trial is to assess the feasibility of conducting a larger confirmatory trial investigating the benefits and harms of an internet-based self-help therapy program, FearFighter™, compared with no intervention for persons with an anxiety disorder.
Design. An investigator-initiated feasibility randomised clinical trial investigating internet-based therapy with FearFighter™ compared with no intervention for persons with an anxiety disorder. We will include 64 participants.
Eligibility criteria. Inclusion criteria: age 18 or older; specific phobia, panic disorder, agoraphobia, or social phobia is the primary diagnosis according to the DSM-IV; and informed consent. Exclusion criteria: suicidal risk; ongoing episode of bipolar disorder or psychosis; concurrent psychological treatment for the anxiety disorder; unable to attend the intervention; or lack of informed consent.
Intervention. The intervention group will use the program FearFighter™, a nine session cognitive behavioural self-help therapy program delivered over the internet during nine weeks. The control group receive no intervention for nine weeks.
Outcomes. Feasibility outcomes are the fraction that are eligible, the fraction that are randomised, and the compliance in the intervention group. Clinical exploratory outcomes are: remission, Beck Anxiety Inventory, Symptom Check List-90R, WHO Well-Being Index, Sheehan Disability Scale, serious adverse events, and behaviour log from FearFighter.
Time schedule. Participants will be included in the trial from July 2015. Results are expected in February 2016.
|Condition or disease||Intervention/treatment||Phase|
|Anxiety||Behavioral: FearFighter||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||64 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Single (Outcomes Assessor)|
|Official Title:||Internet Based Self-help Therapy With FearFighter™ Versus no Intervention for Anxiety Disorders in Adult Persons: a Randomised Feasibility Trial|
|Study Start Date :||August 2015|
|Estimated Primary Completion Date :||December 2016|
|Estimated Study Completion Date :||December 2017|
The experimental group will use the program FearFighter™.
FearFighter™ is a nine session cognitive behavioural self-help therapy program delivered over the internet during nine weeks. Each session on FearFighter excluding the homework takes about 30-40 minutes to finish. A support person will make a weekly contact of 10 minutes in average to secure understanding of the program and compliance.
No Intervention: Control group
The control group receive no intervention for nine weeks.
- Fractions of participants that are eligible and can be randomised [ Time Frame: up to week 10 ]We will determine the fraction of potential participants as the number of eligible persons compared to the number of randomised persons. Here, we consider eligible participants' to be persons who fulfill the inclusion criteria. Exclusion criteria and informed consent is not included in this definition of eligibility.
- Fraction of participants randomised to the experimental group that will comply with the experimental intervention [ Time Frame: up to week 10 ]We will determine the fraction of participants randomised to the experimental group that will comply with the experimental intervention, defined as completing at least 6 of 9 FearFighter™ sessions during the intervention
- Proportion of participants who fulfil the diagnostic criteria for an anxiety disorder at the end of the intervention measured with 'Mini International Neuropsychiatric Interview' (M.I.N.I.) [ Time Frame: up to 37 weeks after start of intervention ]Participants are diagnostic assessed with the 'Mini International Neuropsychiatric Interview' (M.I.N.I.), a short structured interview for the most important psychiatric axis 1 diagnoses in DSM-IV and in ICD-10.
- Symptoms: Beck Anxiety Inventory (BAI) [ Time Frame: Baseline, 10 weeks and 37 weeks after start of intervention ]Beck Anxiety Inventory (BAI) is a 21-items general questionnaire for anxiety symptoms during the last 14 days.
- Symptoms: Symptom check list-90R (SCL-90R) [ Time Frame: Baseline, 10 weeks and 37 weeks after start of intervention ]
Symptom check list-90R (SCL-90R) is a 90-item questionnaire measuring psychological distress and psychopathology (35). Within SCL-90R we use:
- Global severity index (GSI);
- Interpersonal sensitivity subscale;
- Anxiety subscale; and
- Phobic anxiety subscale.
- Functionality: Sheehan Disability Scale (SDS) [ Time Frame: Baseline, 10 weeks and 37 weeks after start of intervention ]
Sheehan Disability Scale (SDS). We assess:
- Occupational function;
- Social function; and
- Family function.
- Quality of life: WHO Well-Being Index [ Time Frame: Baseline, 10 weeks and 37 weeks after start of intervention ]WHO Well-Being Index.,We assess the quality of life.
- Serious adverse events (SAE) [ Time Frame: SAE will be registrered throughout the intervention from week 0 to week 10 ]
Serious adverse events, defined as any adverse event that results in death, is life-threatening, requires hospitalisation or prolongation of existing hospitalisation, results in persistent or significant disability or incapacity, or is a congenital anomaly or birth defect.
Other adverse events, defined as any undesirable medical event occurring to a participant during a clinical trial, which does not necessarily have a causal relationship with the intervention.
- Behaviour log from FearFighter [ Time Frame: Behaviour log will be registrered throughout the intervention from week 0 to week 10 ]Registration of the number of times the participant log on FearFighter.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02499055
|Psychotherapy Center Stolpegård, Mental Health Services in the Capital Region of Denmark|
|Gentofte, Capital Region, Denmark, 2820|
|Study Director:||Marianne Lau, MD||Stolpegaard Psychotherapy Centre. Mental Health Services in the Capital Region of Denmark.|